Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover refractive surgery highlights from AAO, Novartis' takeover of Alcon, and DOJ's increased interest in device manufacturing and safety issues.

You may also be interested in...



ImThera Medical Inc.

Although more than 20 million people in the US are affected by obstructive sleep apnea (OSA), the standard of care for the disorder--a continuous positive airway pressure (CPAP) machine applied at bedtime with a nasal or facial mask to keep airways propped open--carries a noncompliance rate of almost 50%. ImThera Medical Inc. is developing a new implantable neurostimulation device that stimulates certain tongue muscles during sleep to open the upper airway and potentially help patients who are unable or unwilling to use CPAP or pursue surgical alternatives.

AAO Highlights: Back (of the Eye) to the Future

The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.

AAO Highlights: Back (of the Eye) to the Future

The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel